Post-transplant diabetes mellitus: risk reduction strategies in the elderly

Drugs & Aging
Alain DuclosStuart M Flechner

Abstract

New-onset diabetes mellitus in a previously non-diabetic transplant recipient is a serious adverse event that confers significant morbidity and mortality. The most significant consequences of post-transplant diabetes mellitus (PTDM) in solid organ transplant recipients include decreased patient and graft survival, an increased risk of infectious complications, and morbid cardiovascular events. The development of PTDM in the elderly is of particular concern because this group is already at increased risk of progression of cardiovascular disease. Because the elderly, especially those aged >65 years, are the fastest-growing segment of the renal transplant population, attention needs to be given to PTDM risk reduction and post-transplant management. PTDM develops as a consequence of both impaired insulin production and enhanced peripheral insulin resistance. A number of non-modifiable factors such as age, race, family history, hepatitis C, polycystic kidney disease and emerging genetic causes have been identified as risk factors for PTDM. However, a number of modifiable factors can be targets for intervention in high-risk patients, including bodyweight (through dietary restriction and exercise), hypertension, hyperlipidaemia and th...Continue Reading

References

Jan 1, 1995·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·H Klinkmann, J Vienken
Jul 15, 1994·Biochemical and Biophysical Research Communications·K TamuraM Kobayashi
Dec 1, 1995·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·K VareesangthipR Wilkinson
Feb 1, 1996·European Journal of Clinical Investigation·K VareesangthipR Wilkinson
Dec 1, 1996·The American Journal of Physiology·G W Sharp
Aug 1, 1997·Kidney International·K VareesangthipT H Thomas
Sep 15, 1999·Clinical Transplantation·F G CosioR M Ferguson
Feb 9, 2000·JAMA : the Journal of the American Medical Association·K C MangeH I Feldman
Dec 7, 2000·Diabetes Research and Clinical Practice·J H NamK B Huh
Sep 5, 2001·Kidney International·G T JohnC K Jacob
Sep 18, 2001·JAMA : the Journal of the American Medical Association·A H MokdadJ P Koplan
Feb 8, 2002·The New England Journal of Medicine·William C KnowlerUNKNOWN Diabetes Prevention Program Research Group
Mar 13, 2002·Lancet·Raimund Margreiter, UNKNOWN European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group
Sep 18, 2002·Kidney International·Fernando G CosioRonald M Ferguson
Dec 14, 2002·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Jayant T MathewChakko K Jacob
Jan 25, 2003·Transplantation·Ted R MikulsKenneth G Saag
Jan 28, 2003·Diabetes Care·Pascal ImbeaultAngelo Tremblay
Jan 28, 2003·Diabetes Care·Gerald Reaven
Jan 31, 2003·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Jan 31, 2003·The New England Journal of Medicine·Caren G Solomon
Feb 27, 2003·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Bertram L KasiskeArthur J Matas
Mar 12, 2003·Circulation·J Malcolm O ArnoldUNKNOWN HOPE Investigators
Jun 7, 2003·Transplantation·George Tharayil JohnChakko Korula Jacob
Jul 5, 2003·Genes & Development·Ulupi S JhalaMarc Montminy
Dec 31, 2003·Transplantation Proceedings·C R ParikhL Chan
Feb 21, 2004·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Gerhard Opelz, Bernd Döhler
Mar 17, 2004·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Olaf HeiselPaul Keown

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.